A clinical study assessing critical errors, training/teaching time, and preference attributes of the ELLIPTA® dry powder inhaler, in comparison to combinations of dry powder inhalers used to provide triple therapy, in patients with Chronic Obstructive Pulmonary Disease

Trial Identifier: 206215
Sponsor: GlaxoSmithKline
NCTID:: NCT02982187
Start Date: December 2016
Primary Completion Date: June 2017
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Dutch Version

Trial Locations

Country Location
Netherlands ENSCHEDE, Netherlands, 7513 ER
Netherlands NIJVERDAL, Netherlands, 7442 LS
Netherlands ROTTERDAM, Netherlands, 3051 GV
United Kingdom London, United Kingdom, EC1M 6BQ
United Kingdom London, United Kingdom, NW10 7EW